Study of Individual Adult and Pediatric Patient Dose-escalated Interleukin-2 Therapy for Refractory Chronic GVHD
Status:
Completed
Trial end date:
2020-04-22
Target enrollment:
Participant gender:
Summary
This research study is a way of gaining new knowledge about the treatment for cGVHD that has
not responded to steroids. This research study is evaluating a drug called Interleukin-2
(IL-2) as a possible treatment for cGVHD. In this Phase I study, the investigators are
looking to see if 8- week individual patient dose- escalated IL-2 therapy for cGVHD is safe
and its effects on your immune cells.